Clinical Significance of Personalized Neoantigen Vaccine (G1-PES) for The Treatment of Various Types of Advanced Metastatic Cancer Patients in 2001 to 2014: Treatment Case Reports
Clinical Significance of Personalized Neoantigen Vaccine (G1-PES) for The Treatment of Various Types of Advanced Metastatic Cancer Patients in 2001 to 2014: Treatment Case Reports
John A Catanazaro1*, Md Shamsuddin Sultan Khan 1, Mohamed Khadeer Ahmded Basheer 2, Anton Yuryev 1, Andrew Dickens 1
Journal of Precision Biosciences 2(1) 106-115 https://doi.org/10.25163/biosciences.21210160506070820
Submitted: 05 July 2020 Revised: 05 August 2020 Published: 07 August 2020
Neoantigen cancer vaccine is highly effective to treat the various types of cancer which is conducted in 2001 to 2014 at Health and Wellness Institute Integrative Cancer Treatment under the direction of Dr. Catanzaro and his team of physicians.
Abstract
Immunopeptide therapy has provided significant clinical improvements in the treatment of several malignancies. The generation 1 personalized edited sequence (G1-PES) vaccine administered to 43 severe metastatic cancer patients (terminal stage), safely and effectively in Dr. Catanzaro’s clinic in 2001 to 2014. These all patients were considered for 3 to 4 months life support with no hope. Patients were on G1-PES an 18-month therapy program with the objective of achieving remission and cancer free survival within 18 months. Typically, patients received 4 cycles every 12 weeks. The safety and efficacy were assessed through adverse events, progression-free survival (PFS), overall survival (OS) and other parameters. Patients that received G1-PES were free from any serious adverse effects (SAE’s), while receiving and after therapy. Typical reactions included slight fever, flu-like symptoms for 1-2 days and rash at route of administration site that lasted for 2-3 days. All of these minor reactions were self-limiting. Patients had significantly improved quality of life within 1-3 weeks of receiving therapy, with diminishing symptoms associated with their cancer and clinical evidence of cancer regression (p<0.001). G1-PES vaccine was feasible and safe for patients with advanced metastatic cancer. G1-PES vaccine was designed based on T cell-mediated immune response targeting tumor neoantigens as antitumor efficacy.
Key words: Immunotherapy, Cancer, G1-PES (Generation-1 Personalized Edited Sequence), Neoantigen, Personalized vaccine, Peptide vaccine, Advanced malignant tumor
References
Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A. and Jemal A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68, 394-424. https://doi.org/10.3322/caac.21492 PMid:30207593 |
||||
Carreno, B. M. et al. (2015). A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348, 803-808. https://doi.org/10.1126/science.aaa3828 PMid:25837513 PMCid:PMC4549796 |
||||
Chen F., Wei J. and Liu B. (2019). Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. J Clin Invest, 129(5):2056-2070. https://doi.org/10.1172/JCI99538 PMid:30835255 PMCid:PMC6486339 |
||||
Guo Y., Lei K., and Tang L. (2018). Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy. Front Immunol, 9, 1499. doi:10.3389/fimmu.2018.01499. https://doi.org/10.3389/fimmu.2018.01499 PMid:30013560 PMCid:PMC6036114 |
||||
Khong, H. and Overwijk, W.W. (2016). Adjuvants for peptide-based cancer vaccines. Journal for Immunotherapy of Cancer, 4(56). doi:10.1186/s40425-016-0160-y. https://doi.org/10.1186/s40425-016-0160-y PMid:27660710 PMCid:PMC5028954 |
||||
Linnemann, C. et al. (2015). High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat. Med. 21, 81-85. https://doi.org/10.1038/nm.3773 PMid:25531942 |
||||
McGahan JP, Brock JM, Tesluk H, Gu WZ, Schneider P, Browning PD. (1992). Hepatic ablation with use of radio-frequency electrocautery in the animal model. J Vasc Interv Radiol, 3(2), 291-7. doi 10.1016/s1051-0443(92)72028-4. https://doi.org/10.1016/S1051-0443(92)72028-4 |
||||
Ott P. A., Hu Z., Keskin D. B., Shukla S. A., Sun J., Bozym D. J., Zhang W., Luoma A., Giobbie-Hurder A., Peter L., Chen C., Olive O., Carter T. A., Li S., Lieb D. J., Eisenhaure T., Gjini E., Stevens J., Lane W. J., Javeri, I. and Wu, C. J. (2017). An immunogenic personal neoantigen vaccine for patients with melanoma. Nature, 547(7662), 217-221. https://doi.org/10.1038/nature22991 PMid:28678778 PMCid:PMC5577644 |
||||
Peng M., Mo Y., Wang Y., Wu P., Zhang Y., Xiong F., Guo C., Wu,X., Li Y., Li X., Li G., Xiong W. and Zeng Z. (2019). Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer, 18, 128. https://doi.org/10.1186/s12943-019-1055-6 PMid:31443694 PMCid:PMC6708248 |
||||
Prickett, T. D. et al. (2016). Durable complete response from metastatic melanoma after transfer of autologous T cells recognizing 10 mutated tumor antigens. Cancer Immunol. Res. 4, 669-678. https://doi.org/10.1158/2326-6066.CIR-15-0215 PMid:27312342 PMCid:PMC4970903 |
||||
Rizvi, N. A. et al. (2015). Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128. https://doi.org/10.1126/science.aaa1348 PMid:25765070 PMCid:PMC4993154 |
||||
Schumacher, T. et al. (2014). A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512, 324-327. https://doi.org/10.1038/nature13387 PMid:25043048 |
||||
Tran, E. et al. (2014). Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641-645 (2014) https://doi.org/10.1126/science.1251102 PMid:24812403 PMCid:PMC6686185 |
||||
Van Rooij, N. et al. (2013). Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31, e439-e442. https://doi.org/10.1200/JCO.2012.47.7521 PMid:24043743 PMCid:PMC3836220 |
||||
Wang S., Liu H., Zhang X. and Qian F. (2015). Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies. Protein Cell, 6(7), 480-503. https://doi.org/10.1007/s13238-015-0164-2 PMid:25944045 PMCid:PMC4491048 |
||||
Widenmeyer M, Shebzukhov Y, Haen SP, Schmidt D, Clasen S, Boss A, et al. (2011). Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation. Int J Cancer, 128(11), 2653-62 doi 10.1002/ijc.25601. https://doi.org/10.1002/ijc.25601 PMid:20715115 |
||||
Yarchoan M., Johnson B.A., Lutz E.R., Laheru D.A. and Jaffee E.M. (2017). Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer, 17, 209-22. 10.1038/nrc.2016.154. https://doi.org/10.1038/nrc.2017.74 https://doi.org/10.1038/nrc.2016.154 PMid:28233802 PMCid:PMC5575801 |
||||
Yoshida K, Noguchi M, Mine T, Komatsu N., Yutani S., Ueno T., Yanagimoto H., Kawano K., Itoh K., and Yamada A. (2011). Characteristics of severe adverse events after peptide vaccination for advanced cancer patients: Analysis of 500 cases. Oncol Rep, 25(1):57-62. https://doi.org/10.3892/or_00001041 PMid:21152877 |
||||
Yuryev A. and Catanzaro J. (2019). Development of Personalized Therapeutics Using Neo7logix® Precision Profiling for Progressive CNS Inflammation and Autoimmune Disease. Biosciences, 1(1), 001-006. https://doi.org/10.25163/biosciences.112087DB112921119 https://doi.org/10.25163/biosciences.112090DB112921119 |
||||
Yuryev A., Catanzaro J., Khan, M. S. S. (2019a). Development of Personalized Therapeutics Using Neo7logix Precision Profiling in Lung Cancer. Biosciences, 1(1), 016-025. https://doi.org/10.25163/biosciences.112090DB112921119 |
View Dimensions
View Altmetric
Save
Citation
View
Share